The addition of stromal tumour-infiltrating lymphocytes (sTILs) to the PREDICT prognostic model further improves decision-making regarding chemotherapy for early-stage patients with triple-negative breast cancer (TNBC), particularly in identifying those at low risk who may safely waive chemotherapy, according to a study.